Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASPREE to evaluate effects of aspirin in elderly

This article was originally published in The Tan Sheet

Executive Summary

The Health Partners Research Foundation will enroll 19,000 healthy adults aged 70 years and older in the Aspirin in Reducing Events in the Elderly - a study to evaluate whether the potential benefits of low-dose aspirin outweigh the side effects for elderly people. Specifically, ASPREE will weigh the potential of aspirin to prolong healthy lifespan against the risk of bleeding - a well known side-effect of the drug. Researchers will evaluate participants for five years, according to study materials. The study also will evaluate the role aspirin could play in preventing heart disease. Many practitioners prescribe aspirin to help prevent secondary heart attacks and stroke, but this practice came under fire recently, John McNeil, head of the Monash School of Public Health and Preventative Medicine in Australia and a principal investigator for ASPREE, said in a July 6 release

You may also be interested in...

US FDA Puts All China Drug Inspections On Hold Due To Coronavirus Outbreak

February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.

Colgate Was Drawn To Hello Products’ Youthful Lifestyle Branding, And Now It Has A CBD Line

Successfully acquired by Colgate-Palmolive on 31 January, Hello quickly made a statement with the launch of a CBD oral-care range and its first go at lip care, CBD Vegan Lip Balm. Available exclusively through Ulta Beauty, the CBD products have the potential to score well with younger consumers interested in natural ingredients, eco-friendly packaging and, of course, cannabis-based innovations.

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts